Ken Griffin Fulcrum Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 129,600 shares of FULC stock, worth $498,960. This represents 0.0% of its overall portfolio holdings.

Number of Shares

129,600

Previous 195,000 33.54%

Holding current value

$498,960

Previous $696,000 12.5%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$2.97 - $4.84 $3.02 Million - $4.91 Million	-1,015,470 Reduced 75.29%	333,323 $1.57 Million
Q3 2024 Nov 14, 2024	SELL	$3.18 - $9.74 $1.36 Million - $4.17 Million	-428,319 Reduced 24.1%	1,348,793 $4.82 Million
Q2 2024 Aug 14, 2024	BUY	$5.98 - $9.31 $2.7 Million - $4.21 Million	451,733 Added 34.08%	1,777,112 $11 Million
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $525,909 - $941,928	-78,494 Reduced 5.59%	1,325,379 $12.5 Million
Q4 2023 Feb 14, 2024	BUY	$3.18 - $6.86 $476,011 - $1.03 Million	149,689 Added 11.94%	1,403,873 $9.48 Million
Q3 2023 Nov 14, 2023	SELL	$3.25 - $6.08 $813,978 - $1.52 Million	-250,455 Reduced 16.65%	1,254,184 $5.57 Million
Q2 2023 Aug 14, 2023	BUY	$2.26 - $3.8 $2.93 Million - $4.92 Million	1,295,180 Added 618.35%	1,504,639 $4.97 Million
Q1 2023 May 15, 2023	SELL	$2.83 - $13.99 $1.72 Million - $8.49 Million	-606,785 Reduced 74.34%	209,459 $596,000
Q4 2022 Feb 14, 2023	BUY	$5.01 - $8.35 $872,301 - $1.45 Million	174,112 Added 27.11%	816,244 $5.94 Million
Q3 2022 Nov 14, 2022	BUY	$4.92 - $9.1 $2.88 Million - $5.33 Million	586,085 Added 1045.7%	642,132 $5.2 Million

Others Institutions Holding FULC

# of Institutions

130

Shares Held

51.6M

Call Options Held

1.04M

Put Options Held

32.6K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $200M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account